Jeonjinbio Co., Ltd. (KOSDAQ:110020)
South Korea · Delayed Price · Currency is KRW 2,275.00
-75.00 (-3.19%)
At close: Feb 6, 2026
Jeonjinbio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 14,654 | 19,273 | 15,681 | 7,794 | 3,214 | 3,867 |
Other Revenue | -0 | -0 | - | -0 | - | - |
| 14,654 | 19,273 | 15,681 | 7,794 | 3,214 | 3,867 | |
Revenue Growth (YoY) | -26.58% | 22.91% | 101.18% | 142.48% | -16.87% | -2.08% |
Cost of Revenue | 10,598 | 13,271 | 10,861 | 5,836 | 1,898 | 1,698 |
Gross Profit | 4,056 | 6,002 | 4,820 | 1,958 | 1,316 | 2,168 |
Selling, General & Admin | 3,040 | 3,359 | 3,937 | 3,346 | 3,716 | 3,399 |
Research & Development | 428.7 | 361.75 | 447.75 | 421.95 | 363.84 | 344.95 |
Amortization of Goodwill & Intangibles | 8.67 | 16.08 | 20.04 | 27.15 | 30.46 | 112.15 |
Other Operating Expenses | 41.1 | 142.94 | 134.69 | 111.8 | 82.76 | 64.93 |
Operating Expenses | 3,760 | 4,843 | 6,065 | 5,094 | 4,346 | 4,037 |
Operating Income | 295.48 | 1,158 | -1,245 | -3,136 | -3,030 | -1,869 |
Interest Expense | -3.52 | -432.26 | -1,195 | -2,035 | -865.67 | -515.62 |
Interest & Investment Income | 92.29 | 98.86 | 115.08 | 158.71 | 44.12 | 22.51 |
Currency Exchange Gain (Loss) | 10.1 | 6.35 | 2.71 | -25.17 | -8.62 | -11.57 |
Other Non Operating Income (Expenses) | 803.14 | 4,226 | -3,564 | 1,832 | 1,755 | -742.15 |
EBT Excluding Unusual Items | 1,197 | 5,057 | -5,886 | -3,205 | -2,105 | -3,116 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -16.64 |
Gain (Loss) on Sale of Assets | -254.05 | -456.58 | 9.94 | - | -2.91 | -5.63 |
Asset Writedown | -215.23 | -254.15 | -636.91 | - | - | - |
Other Unusual Items | - | - | 73.29 | 91.69 | - | -280.13 |
Pretax Income | 728.22 | 4,346 | -6,440 | -3,113 | -2,108 | -3,418 |
Net Income | 728.22 | 4,346 | -6,440 | -3,113 | -2,108 | -3,418 |
Net Income to Common | 728.22 | 4,346 | -6,440 | -3,113 | -2,108 | -3,418 |
Shares Outstanding (Basic) | 9 | 9 | 7 | 7 | 6 | 5 |
Shares Outstanding (Diluted) | 9 | 9 | 7 | 7 | 6 | 5 |
Shares Change (YoY) | 10.60% | 18.07% | 10.69% | 6.14% | 27.16% | 2.69% |
EPS (Basic) | 80.34 | 505.28 | -884.00 | -473.00 | -340.00 | -701.00 |
EPS (Diluted) | 80.34 | 505.28 | -884.00 | -473.00 | -340.00 | -701.00 |
Free Cash Flow | -355.01 | 2,616 | -960.95 | -5,705 | -4,232 | -8,109 |
Free Cash Flow Per Share | -39.17 | 304.10 | -131.91 | -866.77 | -682.57 | -1662.96 |
Gross Margin | 27.68% | 31.14% | 30.74% | 25.13% | 40.94% | 56.08% |
Operating Margin | 2.02% | 6.01% | -7.94% | -40.23% | -94.26% | -48.34% |
Profit Margin | 4.97% | 22.55% | -41.07% | -39.94% | -65.59% | -88.40% |
Free Cash Flow Margin | -2.42% | 13.57% | -6.13% | -73.19% | -131.67% | -209.71% |
EBITDA | 934.7 | 2,500 | 590.48 | -1,744 | -2,663 | -1,429 |
EBITDA Margin | 6.38% | 12.97% | 3.77% | -22.37% | -82.84% | -36.97% |
D&A For EBITDA | 639.22 | 1,342 | 1,835 | 1,392 | 367.09 | 439.62 |
EBIT | 295.48 | 1,158 | -1,245 | -3,136 | -3,030 | -1,869 |
EBIT Margin | 2.02% | 6.01% | -7.94% | -40.23% | -94.26% | -48.34% |
Advertising Expenses | - | 94.99 | 219.26 | 164.76 | 374.4 | 301.25 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.